



Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer













Correction to: *Nature Communications*

<https://doi.org/10.1038/s41467-022-30666-0>

<https://doi.org/10.1038/s41467-023-35969-4>

Published online: 17 January 2023

 Check for updates

R. C. Coombes , P. D. Badman , J. P. Lozano-Kuehne , X. Liu, I. R. Macpherson , I. Zubairi, R. D. Baird , N. Rosenfeld , J. Garcia-Corbacho , N. Cresti , R. Plummer, A. Armstrong, R. Allerton, D. Landers , H. Nicholas, L. McLellan, A. Lim, F. Mouliere , O. E. Pardo , V. Ferguson & M. J. Seckl 

In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list.

Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023